Clonal hematopoiesis is associated with hematological toxicity during lenalidomide-based therapy for MCL

[1]  Andrew T Nguyen,et al.  Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms , 2022, Blood.

[2]  G. Morgan,et al.  Improving prognostic assignment in older adults with multiple myeloma using acquired genetic features, clonal hemopoiesis and telomere length , 2021, Leukemia.

[3]  R. Fonseca,et al.  Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post‐autologous stem cell transplantation lenalidomide maintenance therapy , 2021, American journal of hematology.

[4]  D. Scott,et al.  Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412 , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  T. Haferlach,et al.  Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients , 2020, Leukemia.

[6]  G. Getz,et al.  Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant , 2020, Nature Communications.

[7]  J. W. Hansen,et al.  Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study , 2020, Leukemia.

[8]  J. Weischenfeldt,et al.  Clonal hematopoiesis evolves from pre-treatment clones and stabilizes after end of chemotherapy in patients with MCL. , 2020, Blood.

[9]  T. Molina,et al.  Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study. , 2018, The Lancet. Haematology.

[10]  G. Mufti,et al.  Clonal hematopoiesis in patients with multiple myeloma undergoing autologous stem cell transplantation , 2018, Leukemia.

[11]  K. Grønbæk,et al.  Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. , 2018, The Lancet. Haematology.

[12]  A. LaCasce,et al.  Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  H. Einsele,et al.  Second primary malignancies in multiple myeloma: an overview and IMWG consensus. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Sonali M. Smith,et al.  Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma. , 2015, The New England journal of medicine.

[15]  Eva Hellström-Lindberg,et al.  TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.